# The Impact of Magnesium on Exercise Tolerance, Quality of Life and Clinical Outcomes in Chronic Heart Failure Patients

Study · id `cardio:ct-nct03840226` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03840226](<https://clinicaltrials.gov/study/NCT03840226>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03840226

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 320 participants.

## Technical summary

Registry record NCT03840226. Randomized; single masking; primary purpose treatment. Start 2019-08-25 (actual); primary completion 2026-01-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 320 participants (planned count; ClinicalTrials.gov record NCT03840226, source copy `cardio:ctgov-nct03840226-2023-12-12`, retrieved 2026-10-26)
- Started: 2019-08-25 (actual) (ClinicalTrials.gov record NCT03840226, source copy `cardio:ctgov-nct03840226-2023-12-12`, retrieved 2026-10-26)
- Primary completion: 2026-01-01 (anticipated) (ClinicalTrials.gov record NCT03840226, source copy `cardio:ctgov-nct03840226-2023-12-12`, retrieved 2026-10-26)
- Completion: 2026-03-01 (anticipated) (ClinicalTrials.gov record NCT03840226, source copy `cardio:ctgov-nct03840226-2023-12-12`, retrieved 2026-10-26)
- Countries: Israel (ClinicalTrials.gov record NCT03840226, source copy `cardio:ctgov-nct03840226-2023-12-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03840226-2023-12-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Impact of Magnesium on Exercise Tolerance, Quality of Life and Clinical Outcomes in Chronic Heart Failure Patients
- Condition: Magnesium Deficiency
- Condition: Heart Failure
- Intervention (Drug): Placebo Oral Tablet
- Intervention (Drug): Magnesium Oxide
- Lead sponsor: Sheba Medical Center
- Lead sponsor class: OTHER\_GOV
- Collaborator: Naveh Pharma (1996) Ltd.
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Sheba Medical Center (`cardio:org-sheba-medical-center`)

## Provenance

Content hash: 8f2c900326552b09bc8fc482d44105dee0edd4119f4a951fe7c3f946e0d41713
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
